Form4insider filings, from the source

SEC Form 3 · accession 0001214659-16-010695

Anthera Pharmaceuticals Inc · ANTH

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
James Pennington
Officer — Interim Chief Medical Officer
Period of report
Apr 1, 2016
Accepted (ET)
Apr 5, 2016 · 1:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001316175

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common Stockholding———17,688D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock option (right to buy)$2.08holding———Oct 24, 2017Oct 24, 2017Common Stock4,746—D
Stock option (right to buy)$12.08holding———Feb 18, 2009Feb 18, 2019Common Stock3,651—D
Stock option (right to buy)F1$4.88holding————May 17, 2023Common Stock25,000—D
Stock option (right to buy)F2$1.58holding————Jan 1, 2025Common Stock20,000—D
Stock option (right to buy)F3$4.75holding————May 21, 2025Common Stock70,000—D
Stock option (right to buy)F4$3.44holding————Jan 15, 2026Common Stock20,000—D
Stock option (right to buy)F5$3.75holding————Mar 4, 2026Common Stock45,000—D

Explanation of responses